/
Oncology
Gastroesophageal Junction Adenocarcinoma
87
Pipeline Programs↗
101
Active Trials↗
54
Companies Involved↗
Gastroesophageal Junction Adenocarcinoma is a moderately active landscape with 87 programs across 54 companies. The most active players are AstraZeneca, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Suzhou Suncadia Biopharmaceuticals Co., Ltd.. 25 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
AstraZeneca
3 programs
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
2 programs
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
1 program
Ono Pharmaceutical Co. Ltd
1 program
Shanghai Henlius Biotech
1 program
Shanghai Runshi Pharmaceutical Technology Co., Ltd
1 program
Pipeline
Programs by Phase
Preclinical12
Phase 13
Phase 247
Phase 325
Approved
No programs
Analysis
Modality Breakdown
78%
Small molecule
62 of 79 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 79 classified programs, each share of the total. Modality classified for 95% of 87 pipeline programs.
Analysis
Trial Status
201
clinical trials
Completed58 · 29%
Recruiting54 · 27%
Not yet recruiting34 · 17%
Terminated19 · 9%
Unknown status19 · 9%
Active, not recruiting12 · 6%
Other5 · 2%
Clinical Trials
Trial Activity
201 trials
A Randomized, Double-Blind, Phase II/III Clinical Study of the Efficacy and Safety of Sintilimab Combined With Chemotherapy With or Without Ipilimumab N01 in Perioperative Treatment of Resectable Gastric/Gastroesophageal Junction Adenocarcinoma
Recruiting·IInnovent Biopharmaceutical Technology (Hangzhou) Co., LTD.·Preclinical·NCT07643623·720 enrolled
Page 1 of 14
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)